DE60223729T2 - Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen - Google Patents

Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen Download PDF

Info

Publication number
DE60223729T2
DE60223729T2 DE60223729T DE60223729T DE60223729T2 DE 60223729 T2 DE60223729 T2 DE 60223729T2 DE 60223729 T DE60223729 T DE 60223729T DE 60223729 T DE60223729 T DE 60223729T DE 60223729 T2 DE60223729 T2 DE 60223729T2
Authority
DE
Germany
Prior art keywords
iodo
hydroxyquinoline
chloro
complex
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223729T
Other languages
German (de)
English (en)
Other versions
DE60223729D1 (de
Inventor
Jorge Setoain Quinquer
Carlos Piera Pena
Isabel Ramirez De Arellano Serna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CETIR CENTRE MEDIC SA
CETIR CT MEDIC S A
Catalana de Dispensacion SA
Barnatron SA
Original Assignee
CETIR CENTRE MEDIC SA
CETIR CT MEDIC S A
Catalana de Dispensacion SA
Barnatron SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CETIR CENTRE MEDIC SA, CETIR CT MEDIC S A, Catalana de Dispensacion SA, Barnatron SA filed Critical CETIR CENTRE MEDIC SA
Application granted granted Critical
Publication of DE60223729D1 publication Critical patent/DE60223729D1/de
Publication of DE60223729T2 publication Critical patent/DE60223729T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60223729T 2002-11-18 2002-11-18 Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen Expired - Lifetime DE60223729T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000537 WO2004045651A1 (es) 2002-11-18 2002-11-18 Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides

Publications (2)

Publication Number Publication Date
DE60223729D1 DE60223729D1 (de) 2008-01-03
DE60223729T2 true DE60223729T2 (de) 2008-10-30

Family

ID=32319763

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223729T Expired - Lifetime DE60223729T2 (de) 2002-11-18 2002-11-18 Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen

Country Status (8)

Country Link
US (1) US20080063599A1 (https=)
EP (1) EP1563852B1 (https=)
JP (1) JP2006514928A (https=)
AU (1) AU2002350751C1 (https=)
CA (1) CA2505506C (https=)
DE (1) DE60223729T2 (https=)
ES (1) ES2297024T3 (https=)
WO (1) WO2004045651A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216949B2 (en) 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム １８ｆ標識物質のための化合物と方法
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CN110759952B (zh) * 2019-09-27 2021-04-20 广西师范大学 基于8-甲氧基喹啉构筑的钴配合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279887A (en) * 1978-11-29 1981-07-21 Medi-Physics, Inc. Amides useful as brain imaging agents
US4360509A (en) * 1979-12-19 1982-11-23 Byk-Mallinckrodt Cil B.V. Vivo radioassay process
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
JP3772506B2 (ja) * 1998-01-19 2006-05-10 三菱化学株式会社 キノリノール誘導体、その金属錯体およびそれを用いた有機電界発光素子
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6589504B1 (en) * 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions

Also Published As

Publication number Publication date
ES2297024T3 (es) 2008-05-01
AU2002350751B2 (en) 2006-04-06
AU2002350751C1 (en) 2006-11-16
AU2002350751A8 (en) 2004-06-15
CA2505506C (en) 2008-07-08
EP1563852A1 (en) 2005-08-17
AU2002350751A1 (en) 2004-06-15
DE60223729D1 (de) 2008-01-03
WO2004045651A1 (es) 2004-06-03
CA2505506A1 (en) 2004-06-03
US20080063599A1 (en) 2008-03-13
EP1563852B1 (en) 2007-11-21
JP2006514928A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
JP4317955B2 (ja) アミロイド斑凝集阻害剤および診断用造影剤
Fodero-Tavoletti et al. Bis (thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease
DE112010000820T5 (de) Verbindungen für nicht-invasive Messung von Aggregaten von Amyloidpeptiden
DE3032781A1 (de) Verfahren zur selektiven ablagerung einer radiopharmazeutischen verbindung in einem zielgewebe oder -organ und verbindungen zur durchfuehrung des verfahrens
DE60223729T2 (de) Verbindungen zur diagnose und überwachung von erkrankungen in zusammenhang mit der bildung von amyloidfibrillen
DE69002627T2 (de) 99 m Tc (III) herzmuskelbildende Mittel, wirksam beim Menschen.
DE69930381T2 (de) Spect abbildungsreagenzien für serotonintransporter
DE19536781A1 (de) Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE19536783A1 (de) Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
DE69333611T2 (de) Radiomarkierte mehrwertige phenolverbindungen
DE4428874A1 (de) Dimere DTPA-Derivate und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
EP0398024B1 (de) Konjugate zur Tumorlokalisation und/oder Tumortherapie
DE4311022C2 (de) Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
WO1995012613A1 (de) Metallbindende cysteinfreie peptide für diagnose und therapie, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69117741T2 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
WO2004043496A1 (de) Fluor-18-markierte fluorchinolone
DE4337600A1 (de) N-Alkyl-Peptidchelatbildner, deren Metallkomplexe mit Radionukliden, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Zusammesetzungen
DE102023133281B4 (de) Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika
DE3623438C2 (de) In 2-Stellung mit radioaktivem Iod markierte Ergolinylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Diagnostika
EP3724168B1 (de) Neue daza-chelatoren als liganden in der leberbildgebung
EP0745082A1 (de) Substituierte 1,3,8-triaza-spiro(4,5)-decan-4-on-derivate als vorstufen zur herstellung von pharmazeutika
DE69824147T2 (de) Technetium-99m markierte Diäthylentriaminpentaessigsäure-Diester und Verfahren zu deren Herstellung
DE2145282A1 (de) 1-(jodhydroxyphenyl)-2-aminopropanderivate und verfahren zu ihrer herstellung
DE102017103600A1 (de) Radioaktiv markiertes beta-Galactosidase Substrat für PET Bildgebung der Seneszenz
EP0542216A1 (de) Diaminomercapto (thio)ether als Komplexbildner für in der Nuklearmedizin einsetzbare Nuklide, Verfahren zur Herstellung der Komplexe, sowie Markierungskits, enthaltend diese Komplexe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition